SciELO - Scientific Electronic Library Online

vol.29 número1Terapêutica biológica da asma grave em crianças e adolescentes índice de autoresíndice de materiabúsqueda de artículos
Home Pagelista alfabética de revistas  

Servicios Personalizados




Links relacionados

  • No hay articulos similaresSimilares en SciELO


Revista Portuguesa de Imunoalergologia

versión impresa ISSN 0871-9721


PEREIRA, Mariana et al. Control of allergic disease in patients under treatment with subcutaneous allergen immunotherapy. Rev Port Imunoalergologia [online]. 2021, vol.29, n.1, pp.13-25.  Epub 31-Mar-2021. ISSN 0871-9721.


Measuring the control of allergic diseases is crucial to assess the outcomes of subcutaneous allergen immunotherapy (SCIT).


To describe the control of allergic diseases (asthma, rhinitis, conjunctivitis) in patients treated with SCIT.


A descriptive study was carried out of all patients aged >12 years under SCIT between March 2017 and June 2019 at the allergy units of CUF‑Porto and who answered ≥1 evaluation questionnaire prior to SCIT administration (the most recent assessment of each individual was analysed). The questionnaire included CARAT and a visual analogue scale (VAS) for eye symptoms (from 0 - minimum - to 10 cm - maximum). Control of asthma and rhinitis was defined as CARAT total (T) score>24; the control of upper (U) and lower (L) airways was based on CARAT sub‑scores (CARAT U >8 and CARAT L ≥16, respectively).


We included 209 patients, 96 (46%) female and 62 (30%) aged <18 years. All patients had rhinitis and 32% (n=67) had asthma. 34% of patients were in the first year of SCIT and 40% were in the third or more. CARAT mean score (standard deviation) was 24.6(4.2), with 57% (n=119) controlled patients. 75% (n=50) of those with asthma had controlled lower airways symptoms but only 47% (n=98) had controlled upper airways symptoms. CARAT T and CARAT U scores were not significantly correlated with the duration of SCIT (r=0.082 and - 0.011, respectively), however, CARAT L presented a positive correlation (r=0.203). The median score (interquartile range) for ocular symptoms VAS was 0.3(0.8) cm; 79% of patients scored <1 cm.


Almost 60% of the patients assessed by CARAT showed control of respiratory allergic disease, but only 47% had controlled rhinitis. Although we observed a higher proportion of controlled patients than published in other settings, further real‑life studies are needed to strengthen evidence of SCIT effectiveness.

Palabras clave : Allergy; asthma; conjunctivitis; disease control; rhinitis; subcutaneous allergen immunotherapy.

        · resumen en Portugués     · texto en Portugués     · Portugués ( pdf )